Jennifer R. Diamond

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · The Lancet · 2020 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +16

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat et al. · New England Journal of Medicine · 2019 · 850 citations

Medicine, Oncology, Pharmacology +17

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

Aditya Bardia, Ingrid A. Mayer, Jennifer R. Diamond et al. · Journal of Clinical Oncology · 2017 · 409 citations

Medicine, Oncology, Pharmacology +12

Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up

Sylvia Adams, Jennifer R. Diamond, Erika Hamilton et al. · JAMA Oncology · 2018 · 283 citations · Full text

Medicine, Oncology, Pharmacology +17

Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts

Anna Capasso, Julie Lang, Todd M. Pitts et al. · Journal for ImmunoTherapy of Cancer · 2019 · 178 citations · Full text

Life Sciences, Immunology, Oncology +17